FDA Weighs First-in-Human Pilot as Trials Head Offshore

The FDA is working with drugmakers and academic medical centers, including Amgen and Memorial Sloan Kettering Cancer Center, on a pilot program to accelerate first-in-human clinical trials in response to China's and Australia's speed advantage in early-phase studies.

The U.S. Food and Drug Administration is working through the mechanics of a pilot program designed to get experimental drugs into their first human subjects faster, according to Endpoints News. Amgen and Memorial Sloan Kettering Cancer Center are among the stakeholders in the discussions, which are aimed squarely at a competitive problem regulators have watched build for years: China and Australia now dominate the business of starting early-phase trials quickly.

The details are still being negotiated, and that is the substance of the story. A pilot of this kind lives or dies on specifics — which sponsors qualify, which molecule classes are eligible, what review clock replaces the standard one, and what safety data a sponsor must hand over in exchange for moving faster. None of those parameters has been settled publicly.

Where the U.S. loses time on a first-in-human study

In the United States, a sponsor cannot dose a healthy volunteer or a patient until it has filed an investigational new drug application, or IND — the package of manufacturing, toxicology and trial-design data the FDA reviews before human testing begins. Assembling that package is itself a long job, and the review that follows adds more time before the first patient is dosed.

Australia's appeal is procedural rather than scientific: early-phase studies there can proceed through a notification route overseen by human research ethics committees, without a full central regulatory filing first. China's appeal is scale and throughput — sites that can enroll quickly and a regulator that has compressed its own early-phase timelines. For a small biotech burning cash, or a large one running dozens of programs in parallel, weeks of saved calendar time convert directly into money and into position against a rival working on the same target.

That is the arbitrage the pilot is meant to close. The prize is not a scientific advantage — the same molecule is being tested either way — but the location of the first data, the first investigators, the first patients and, over time, the clinical infrastructure that grows around them.

Why Amgen and an academic cancer center are at the table

The pairing of a large-cap developer with a major academic center is telling. Amgen brings volume: a sponsor with many programs entering the clinic each year is the natural test case for whether a faster pathway holds up under repetition. Memorial Sloan Kettering brings the other half — the phase 1 units, investigators and patient populations where first-in-human oncology work actually happens, and the institutional review machinery that has to move in step with any accelerated federal clock.

Academic centers have a particular stake here. When a sponsor decides to run its first study in Sydney or Shanghai rather than New York, the U.S. site loses more than a contract. It loses the early relationship with the asset, the tissue and biomarker work that follows, and often the later-phase business too. A pilot that keeps first-in-human studies onshore is, for those institutions, a pipeline question as much as a policy one.

What the market is pricing, and what it is not

Nothing about a pilot at this stage is a valuation event. Amgen (NASDAQ: AMGN) last traded at $442.24, down 0.36% on the day from a prior close of $443.84, with a session range of $441.26 to $447.03, as of the close on Aug. 25, 2026. That is a quiet tape for a company named in a regulatory story — appropriately so, since no product, no readout and no approval is at issue.

The broader market closed firmer the same session. The S&P 500 tracker (SPY) finished at $765.91, up 0.32%; the Nasdaq 100 tracker (QQQ) closed at $710.72, up 0.62%; and the Dow tracker (DIA) ended at $535.24, up 0.30%. Amgen's small decline against a modestly higher market says nothing about the pilot and everything about the fact that policy design does not move large-cap biopharma shares.

Where it would eventually show up is in development cost and cycle time — the least glamorous and most durable levers in drug development. A sponsor that reaches first-in-human dosing sooner reaches its first human pharmacokinetic and safety signal sooner, and can kill a bad program or accelerate a good one earlier. Those decisions compound across a pipeline in a way no single trial result does.

The design questions that will decide whether it works

Several unresolved issues will determine whether the pilot changes behavior or simply adds a lane no one uses:

• Eligibility. If the pathway is limited to well-characterized modalities, it will help least where speed matters most — novel platforms with thin precedent.
• Capacity. A faster review clock requires reviewer time. Any pilot competing for the same staff that handles the existing IND workload risks moving the bottleneck rather than removing it.
• Safety trade-offs. First-in-human studies are where the risk of a serious, unanticipated event is highest. A single bad outcome in a pilot cohort would end the experiment regardless of its statistical merits.
• Ethics committee alignment. Australia's speed comes partly from decentralized ethics review. A faster federal clock with unchanged institutional review timelines saves less than it appears to.
• Scope. A pilot large enough to matter competitively is also large enough to require resourcing that has not been announced.

What to watch from here

The near-term markers are procedural. Watch for a formal FDA announcement naming participating sponsors and sites, and for any published criteria on eligibility and review timing — that is the point at which sponsors can model whether the pathway beats a flight to Australia. Watch, too, for which academic centers sign on beyond Memorial Sloan Kettering; a pilot concentrated at two or three elite institutions would be a proof of concept, not a shift in where American early-phase research happens.

Longer term, the test is behavioral rather than regulatory. Trial registrations are public. If the share of first-in-human studies for U.S.-headquartered sponsors that begin at U.S. sites starts to rise, the pilot worked. If sponsors keep filing their first studies offshore and using the U.S. route later, then the constraint was never the review clock — it was the cost and complexity of running an early trial in America, and a pilot cannot fix that.

For now, the useful read is that the FDA has accepted the premise of the complaint. Industry has argued for years that early-phase work is drifting abroad; the agency convening sponsors and academic centers to design a remedy is an acknowledgment that the drift is real and that the calendar, not the science, is the reason for it.

Key facts

• AMGN last close: $442.24, -0.36%, as of Aug. 25, 2026, 20:00 GMT
• Program stage: Pilot details still being negotiated between FDA and stakeholders
• Named participants: Amgen; Memorial Sloan Kettering Cancer Center
• Competitive target: China and Australia's dominance in fast early-phase trial starts

Frequently asked questions

What is a first-in-human trial?

A first-in-human study is the first time an experimental drug is given to people, usually healthy volunteers or, in oncology, patients with advanced disease. It tests safety, tolerability and how the body processes the compound rather than whether it works. In the United States it cannot begin until the FDA has reviewed an investigational new drug application.

Why are China and Australia faster at early-phase trials?

Australia allows many early-phase studies to proceed through a notification route overseen by human research ethics committees rather than a full central regulatory filing first. China offers scale and rapid patient enrollment alongside compressed regulatory timelines. Both let sponsors reach first dosing sooner than the standard U.S. investigational new drug pathway typically permits.

What would the FDA pilot actually change?

The details have not been settled publicly. The stated aim is to accelerate the start of first-in-human trials, which in practice means altering how quickly an investigational new drug application is reviewed and what data a sponsor must supply up front. Eligibility criteria, participating sponsors and the replacement review clock remain under negotiation.

Is Amgen's stock affected by the pilot discussions?

Not meaningfully at this stage. Amgen last traded at $442.24, down 0.36% from a prior close of $443.84, as of the Aug. 25, 2026 close, while the S&P 500 tracker rose 0.32%. A pilot program still being designed involves no product approval, trial readout or revenue event, so it carries no immediate valuation consequence.

Why do academic medical centers care about this?

Phase 1 units at academic centers are where first-in-human studies are physically run. When a sponsor takes that first study offshore, the U.S. site loses the contract, the early relationship with the drug, associated biomarker and tissue work, and often the later-stage trial business that follows the asset through development.

How would anyone know if the pilot succeeded?

Trial registrations are public, so the measurable test is whether a larger share of first-in-human studies run by U.S.-based sponsors begins at U.S. sites. If sponsors continue starting abroad and filing in America later, the binding constraint was the cost and complexity of running early trials domestically rather than the review timeline itself.

Sources

• Amgen, academic centers weigh new FDA pilot to speed early drug trials — Endpoints News

Photo: Gustavo Fring · Pexels Licence — source